Abstract
When Pierre Lemieux and his team at Acasti Pharma went looking for a pharmaceutical manufacturing partner, they had a surprising amount of trouble finding one. The reason was the type of drug they are developing. The active ingredient in Acasti’s lead product, which lowers triglyceride levels in people at risk of cardiovascular disease, is an extract from krill oil, and not everyone wants to work with krill oil. For starters, natural product extraction is an art not widely practiced among drug outsourcing firms. In addition, krill are shrimplike crustaceans, and some potential partners were concerned about contaminating their facilities with shellfish allergens. On top of that, extracting the active ingredient involves acetone, a flammable solvent some companies weren’t prepared to handle. A krill oil plant operated by Acasti’s then parent company exploded in 2012, killing three people. But Acasti kept looking. It was having success in early trials of its
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
